Clarus Therapeutics

The roughly 30 percent gain notched up by Lipocine Inc (NASDAQ: LPCN) in the three sessions following its announcement of a patent infringement lawsuit win could all be soon wiped out. The company announced last Friday that a U.S. district court has dismissed a lawsuit filed by Clarus Therapeutics...

Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks. September 26: Positive Top-Line Results The company announced...